These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19775344)

  • 1. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
    Almasi CE; Høyer-Hansen G; Christensen IJ; Pappot H
    APMIS; 2009 Oct; 117(10):755-61. PubMed ID: 19775344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
    Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
    Almasi CE; Drivsholm L; Pappot H; Høyer-Hansen G; Christensen IJ
    APMIS; 2013 Mar; 121(3):189-96. PubMed ID: 23030781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
    Almasi CE; Høyer-Hansen G; Christensen IJ; Danø K; Pappot H
    Lung Cancer; 2005 Jun; 48(3):349-55. PubMed ID: 15893003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.
    Almasi CE; Christensen IJ; Høyer-Hansen G; Danø K; Pappot H; Dienemann H; Muley T
    Lung Cancer; 2011 Dec; 74(3):510-5. PubMed ID: 21640427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
    Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
    Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
    Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase receptor variants in tissue and body fluids.
    Høyer-Hansen G; Lund IK
    Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
    Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Lund IK; Thurison T; Høyer-Hansen G; Mau-Sørensen M
    Clin Biochem; 2014 May; 47(7-8):599-604. PubMed ID: 24530340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
    Hansen LV; Skov BG; Ploug M; Pappot H
    Lung Cancer; 2007 Nov; 58(2):260-6. PubMed ID: 17706320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
    Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
    Piironen T; Laursen B; Pass J; List K; Gårdsvoll H; Ploug M; Danø K; Høyer-Hansen G
    Clin Chem; 2004 Nov; 50(11):2059-68. PubMed ID: 15345662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
    Jumper C; Cobos E; Lox C
    Anticancer Res; 2002; 22(4):2073-6. PubMed ID: 12174885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
    Almasi CE; Brasso K; Iversen P; Pappot H; Høyer-Hansen G; Danø K; Christensen IJ
    Prostate; 2011 Jun; 71(8):899-907. PubMed ID: 21456072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
    Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
    Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.